Oncology & Immuno-Oncology
PhoreMost’s internal oncology assets focus on key oncogenic drivers with multiple previously undruggable targets currently being progressed including multiple K-RAS synthetic lethal targets.
In partnership with Sentinel Oncology, PhoreMost is also progressing allosteric PLK1 inhibitors, currently in development for the treatment of Glioma.
Predominantly focused on the generation of neoantigens, PhoreMost’s Immuno-oncology programmes are pursuing multiple routes to enhance the body’s response to cancer by making tumours more visible to the immune system. Discover more
Targeted Protein Degradation
In applying the SITESEEKER® platform to Targeted Protein Degradation, we have identified a portfolio of novel, functional E3 Ligase binders. Based on these observations, PhoreMost are aiming to develop a suite of small molecule assets that will unlock new E3 ligase based therapeutic strategies. Discover More
Neurodegenerative disorders and diseases of ageing
Ageing related diseases are a core future focus of PhoreMost. The SITESEEKER® platform is currently active in screening for senescence, autophagy, plaque formation and targeted protein degradation. Discover more
PhoreMost is actively engaged with several commercial SITESEEKER® collaborations with Pharma and Biotechnology companies. If you would like to learn more about partnership opportunities, contact us. Discover more